Differences in compliance patterns across the selective serotonin reuptake inhibitors (SSRIs)

References

• Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8–19
   PubMed Web of Science ®Google Scholar
• Kessler RC, Nelson CB, McGonagle KA, et al. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry Suppl 1996;168:17–30
   Google Scholar
• Arabian SR, Gorman JM. A review of the diagnosis, pharmacologic treatment, and economic aspects of anxiety disorders. Primary Care Companion J Clin Psychiatry 2001;3:110–7
   PubMedGoogle Scholar
• Greenberg PE, Birnbaum HG, Lowe SW, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64:1465–75
   PubMed Web of Science ®Google Scholar
• Sramek JJ, Zarotsky V, Cutler NR. Generalized anxiety disorder. Drugs 2002;11:1635–48
   Google Scholar
• Blanco C, Raza MS, Schneier FR, et al. The evidence-based pharmacological treatment of social anxiety disorder. Int J Neuropsychopharm 2003;6:427–42
   PubMed Web of Science ®Google Scholar
• IMS Health. IMS reports 11.5% dollar growth in 2003 US prescription sales. IMS National Sales Perspectives. 2004. Available from www.imshealth.com [Accessed 29 October 2004]
   Google Scholar
• Lin EHB, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995;33:67–74
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Li Z, McKendrick J. Selective serotonin reuptake inhibitor treatment in the UK: risk of relapse or recurrence of depression. Br J Psychiatry 2000;177:163–8
   Google Scholar
• Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998;55:1128–32
   PubMed Web of Science ®Google Scholar
• Eaddy M, Sheehan D, Sarnes M, et al. SSRI utilization patterns and the economic consequences of early discontinuation. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1–6, 2004; New York, NY
   Google Scholar
• Eaddy M, Bramley T, Regan T. Time to antidepressant discontinuation: a comparison of controlled-release paroxetine and immediate-release selective serotonin-reuptake inhibitors. Manag Care Interface 2003;1:22–7
   Google Scholar
• Sheehan D, Eaddy M, Sarnes M, et al. Evaluating the economic consequences of early antidepressant treatment discontinuation. J Clin Psychopharmacol 2004;24:544–8
   PubMed Web of Science ®Google Scholar
• Sood N, Treglia M, Obenchain RL, et al. Determinants of antidepressant treatment outcomes. Am J Manag Care 2000;6:1327–36
   PubMed Web of Science ®Google Scholar
• DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for non compliance with medical treatment: meta-analysis of effects of anxiety and depression on patient adherence. Arch Intern Med 2000;160:2101–7
   Google Scholar
• Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49: 196–201
   PubMed Web of Science ®Google Scholar
• Giannetti VJ. Adherence with antidepressant medication. Manag Care 2004;13:42–7
   PubMedGoogle Scholar
• Golden RN, Nemeroff CB, McSorley P, et al. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J Clin Psychiatry 2002;63:577–84
   PubMed Web of Science ®Google Scholar
• Steiner J, Prochazka A. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105–16
   PubMed Web of Science ®Google Scholar
• National Committee for Quality Assurance (NCQA). Health Plan Employer Data and Information Set (HEDIS). 2005
   Google Scholar
• Thompson D, Buesching D, Gregor KJ, et al. Patterns of antidepressant use and their relation to cost of care. Am J Manag Care 1996;2:1239–46
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83
   PubMedGoogle Scholar
• Deyo R, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD9-CM administrative databases. J Clin Epidemiol 1992;45: 613–9
   Google Scholar
• Eaddy M, Sarnes M, Regan T, et al. Examining the relationship between length of selective serotonin reuptake inhibitor treatment and the risk of hospitalization in a naturalistic managed care setting. Poster presented at: 2004 Educational Conference of the Academy of Managed Care Pharmacy; October 13–16, 2004; Baltimore, MD
   Google Scholar
• National Committee for Quality Assurance. The State of Health Care Quality: 2004. Available from http://www.ncqa.org/communications/S0MC/S0HC2004.pdf [Accessed 25 July 2005]
   Google Scholar
• Anderson IM. Meta-analytical studies on new antidepressants. Br Med Bull 2001;57:161–78
   PubMed Web of Science ®Google Scholar
• Bakish D. The patient with comorbid depression and anxiety: the unmet need. J Clin Psychiatry 1999;60(Suppl 6):20–4
   PubMed Web of Science ®Google Scholar
• Rickels K, Rynn M. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2002;63(Suppl 14):9–16
   PubMedGoogle Scholar
• Eaddy M, Lennert B, Regan T. Incorporating compliance and persistency outcomes into disease management: The National Depression/Anxiety Managed Care Database Study. Presented at: The Disease Management Association of America 5th Annual Disease Management Leadership Forum; October 12–15, 2003; Chicago, Illinois
   Google Scholar
• Rost K, Smith R, Matthews DB, et al. The deliberate misdiagnosis of major depression in primary care. Arch Fam Med 1994;3:333–7
   PubMedGoogle Scholar
• Hughes DA, Bagust A, Haycox A, et al. The impact of noncompliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 2001;10:601–15
   PubMed Web of Science ®Google Scholar
• White TJ, Vanderplas A, Ory C, et al. Economic impact of patient adherence with antidepressant therapy within managed care organizations. Dis Manag Health Outcomes 2003;11:817–22
   Google Scholar